Neuphoria Therapeutics Inc.
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q4 | -0.91 | $1M | -$12.3B |
| 2026 Q3 | -0.09 | $0 | -$4M |
| 2025 Q2 | 0.41 | $0 | -$6M |
| 2025 Q1 | -6.67 | $0 | -$4M |
| 2025 Q4 | -4.65 | -$10M | $74M |
| 2025 Q3 | 6.55 | $15M | $11M |
| 2024 Q2 |
| -0.01 |
| $662,715 |
| -$3M |
| 2024 Q1 | -0.00 | $10M | -$4M |